NewsXbrane Biopharma releases interim report for the period July to September 2017

Xbrane Biopharma ABs interim report for the period July – September 2017 is now available on the Company’s website, www.xbrane.com.

July to September

  • Revenue SEK -47 thousand (-)
  • EBITDA SEK -8,181 thousand (-8,433)
  • Profit or loss after tax SEK -9,092 thousand (-9,027)
  • Research and development expenses in % of total operating expenses 80% (80%)
  • Cash and cash equivalents SEK 23,624 thousand (43,923)
  • Earnings per share before dilution SEK -1.53 (-1.95)
  • Earnings per share after dilution SEK -1.38 (-1.55)

Significant events for the period

  • Spherotide receives market approval in Iran
  • Xbrane confirms order of Spherotide to a value of SEK 8.5 million
  • The Board decided to initiate the preparation for a listing change to Nasdaq OMX Main list

Significant events after the period

  • Xbrane Biopharma AB appoints Dina Jurman, Head of Clinical Affairs, as a member of the management team

Link to the report

For further information, please contact:
Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen
CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636
E:
susanna.helgesen@xbrane.com

 

This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation no. 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 November 13, 2017.